Press releases
-
11/09/2026, Sophia Antipolis, France Median Technologies to Participate in the Stifel 2026 Healthcare Conference
Oran MUDUROGLU, Chairman of the Board of Median Technologies and President of Median eyonis Inc., Median’s U.S. subsidiary responsible for the U.S. commercialization of eyonis® LCS, will participate in a fireside chat.Read more Download 20261109_PR_StifelHCConference_EN.pdf -
11/05/2026, Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20261105_PR_shares_votingrights_October2026.pdf -
10/29/2026, Sophia Antipolis, France Median Technologies Reports H1 2026 Financial Results and Q3 Business Highlights – eyonis LCS Advances U.S. Commercial Rollout as iCRO Achieves Double-Digit Revenue Growth and Record €90.9 million in Q3
eyonis® LCS Advances U.S. Commercial Rollout, as iCRO Achieves Double-Digit Revenue Growth and Record €90.9 Million Order Backlog in Q3Read more Download 20261029_PR_HY2026Q32026_EN_Final2.pdf -
10/21/2026, Sophia Antipolis, France Median Technologies to Showcase iCRO’s Central and AI-powered Imaging Services for Oncology Clinical Trials at ESMO 2026
The Company will welcome attendees at booth #1098, Hall 10 from October 23 to 26Read more Download 20261021_PR_ESMO2026_EN.pdf -
10/20/2026, Sophia Antipolis, France Median Technologies Strengthens Its Engagement with the International Lung Cancer Screening Community at the 50th I-ELCAP Conference in New York
Median Technologies and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at this landmark meeting of the international lung cancer screening communityRead more Download 20261020_PR_ielcap_EN_final.pdf -
10/14/2026, Sophia Antipolis, France eyonis Inc., a Median Technologies company, to present study results supporting eyonis® LCS performance claims at CHEST 2026
CHEST 2026 provides an important opportunity to engage with pulmonologists, a key stakeholder group for adoption of AI-enabled decision support solutions in lung cancer screeningRead more Download 20261014_PR_CHEST2026_EN_final.pdf -
10/12/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2026
Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20261012_PR_shares_votingrights_September2026.pdf -
09/15/2026, Sophia Antipolis, France Median Technologies Secures one of the Largest iCRO Projects in its History
The project was awarded by a leading European pharmaceutical company and long-standing Median customer, whose oncology franchise has become its primary growth driver. The contract has a total value of €8.4 million (approximately $9.5 million).Read more Download 20260915_PR_iCROcontract_EN_final.pdf -
09/10/2026, Sophia Antipolis, France H2 2026 Financial Communication Calendar
Median Technologies to release H1 2026 results on October 29, 2026 after market closeRead more Download 20260910_PR_H22026_calendar_EN.pdf -
09/08/2026, Sophia Antipolis, France Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2026
Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.Read more Download 20260908_PR_shares_votingrights_August2026.pdf